Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-NF2 Rescue Study (HLA-A*24:02-restricted VEGFR1/2 peptide vaccine in NF2-related schwannomatosis)
jRCT2031240608Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of OCV-101 and OTS-102 in neurofibromatosis type 2 (NF2) and acoustic neuroma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Toxicity profile (frequency and severity). Started Feb 2025; status: recruiting.
02
Drugs
OCV-101OTS-102
03
Conditions
neurofibromatosis type 2 (NF2)acoustic neuroma
Beyond the preview
Go deeper on jRCT2031240608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240608.